View ValuationElekta 향후 성장Future 기준 점검 4/6Elekta (는) 각각 연간 42.2% 및 4.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 42.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 20.2% 로 예상됩니다.핵심 정보42.2%이익 성장률42.84%EPS 성장률Medical Equipment 이익 성장13.3%매출 성장률4.2%향후 자기자본이익률20.23%애널리스트 커버리지Good마지막 업데이트22 Jun 2026최근 향후 성장 업데이트공시 • May 28+ 2 more updatesElekta AB (publ) Provides Earnings Guidance for the Fiscal Year 2026/2027Elekta AB (publ) provided earnings guidance for the fiscal year 2026/2027. For the year, The company expects net sales in constant currency to increase year over year, with an improvement in the EBIT margin.공시 • Aug 28Elekta AB (publ) Provides Earnings Guidance for the Second Quarter 2025-2026 and Reiterates Earnings Guidance for the Year 2025-2026Elekta AB (publ) provided earnings guidance for the second quarter 2025-2026 and reiterated earnings guidance for the year 2025-2026. The company expects net sales for second quarter to be negatively impacted by a continued weak US development as well as a negative effect from last year's low order intake in China. However, The company expects sales in China to start to recover during the second half of 2025/26. Furthermore, company expect a continuous negative impact on earnings from FX at current exchange rates and from tariffs in second quarter. The company reiterates full year 2025-2026 outlook, where the company expects net sales in constant currency to grow year-over-year.공시 • May 25+ 1 more updateElekta AB (publ) Provides Earnings Guidance for the Fiscal Year from 2022-2023 to 2024-2025Elekta AB (publ) provided earnings guidance for the fiscal year from 2022-2023 to 2024-2025. For the period, the company expects net sales CAGR of above 7%.모든 업데이트 보기Recent updatesDeclared Dividend • May 31Final dividend of kr1.20 announcedShareholders will receive a dividend of kr1.20. Ex-date: 4th September 2026 Payment date: 10th September 2026 Dividend yield will be 27%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (66% cash payout ratio). The dividend has increased by an average of 17% per year over the past 10 years. However, payments have been volatile during that time.Reported Earnings • May 28Full year 2026 earnings released: kr1.36 loss per share (vs kr0.62 profit in FY 2025)Full year 2026 results: kr1.36 loss per share (down from kr0.62 profit in FY 2025). Revenue: kr16.7b (down 7.2% from FY 2025). Net loss: kr519.0m (down 319% from profit in FY 2025). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance.공시 • May 28+ 2 more updatesElekta AB (publ) Provides Earnings Guidance for the Fiscal Year 2026/2027Elekta AB (publ) provided earnings guidance for the fiscal year 2026/2027. For the year, The company expects net sales in constant currency to increase year over year, with an improvement in the EBIT margin.Board Change • May 21High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Jan De Witte was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공시 • May 19Elekta AB (publ) to Report Fiscal Year 2026 Final Results on Jul 03, 2026Elekta AB (publ) announced that they will report fiscal year 2026 final results at 9:00 AM, Central European Standard Time on Jul 03, 2026공시 • Mar 05+ 1 more updateElekta AB (publ) to Report Q2, 2027 Results on Nov 25, 2026Elekta AB (publ) announced that they will report Q2, 2027 results on Nov 25, 2026공시 • Feb 26Elekta AB (publ), Annual General Meeting, Sep 03, 2026Elekta AB (publ), Annual General Meeting, Sep 03, 2026.공시 • Jan 23Elekta AB Appoints Tomas Eliasson as Vice Chair of the Board, Effective January 23, 2026Elekta AB has established the role of Vice Chair of the Board and appointed Tomas Eliasson to this position, effective January 23, 2026. Tomas Eliasson has been a member of Elekta’s Board of Directors since 2023 and the Chair of its Audit Committee since 2024. He brings extensive experience from senior leadership and board roles in global industrial and technology-driven companies. His background includes deep expertise in finance, governance and strategy, supporting Elekta’s continued focus on long-term value creation.공시 • Jan 16Elekta Receives FDA 510(K) Clearance for Elekta Evo Linear AcceleratorElekta announced that its Elekta Evo CT-Linac has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This milestone makes the system available to radiation oncology professionals in the United States. When delivering radiation therapy, clinicians require high-quality images that allow them to identify tumors and organs-at-risk. Evo addresses this with Iris®? high-definition, AI-enhanced imaging, which allows physicians to see target areas and critical structures for every fraction with greater clarity. In Europe and other countries, Elekta Evo continues to gain traction, setting new benchmarks in radiation therapy as more clinics adopt its innovative treatment capabilities.공시 • Sep 04+ 1 more updateElekta AB (Publ) Elects Jan De Witte as DirectorElekta AB (publ) at its AGM held on September 4, 2025 approved to elect Jan De Witte, as Director for the period until the end of the next Annual General Meeting.공시 • Aug 28Elekta AB (publ) Provides Earnings Guidance for the Second Quarter 2025-2026 and Reiterates Earnings Guidance for the Year 2025-2026Elekta AB (publ) provided earnings guidance for the second quarter 2025-2026 and reiterated earnings guidance for the year 2025-2026. The company expects net sales for second quarter to be negatively impacted by a continued weak US development as well as a negative effect from last year's low order intake in China. However, The company expects sales in China to start to recover during the second half of 2025/26. Furthermore, company expect a continuous negative impact on earnings from FX at current exchange rates and from tariffs in second quarter. The company reiterates full year 2025-2026 outlook, where the company expects net sales in constant currency to grow year-over-year.공시 • May 29Elekta AB (publ), Annual General Meeting, Sep 04, 2025Elekta AB (publ), Annual General Meeting, Sep 04, 2025.공시 • May 28+ 1 more updateElekta AB (publ) Proposes Dividend for the Fiscal Year 2024/25The Board of Directors of Elekta AB (publ) proposed a dividend of SEK 2.40 (SEK 2.40) per share (paid in two installments) for 2024/25 amounting to SEK 917 million.공시 • May 19+ 1 more updateElekta AB (publ) to Report Q3, 2026 Results on Mar 05, 2026Elekta AB (publ) announced that they will report Q3, 2026 results on Mar 05, 2026공시 • May 05Elekta Announces Use of Its 1.5T Elekta Unity MR-LinacElekta announced that use of its 1.5T Elekta Unity MR-Linac can enable doctors to reduce the radiation dose to key structures responsible for erection among men being treated for prostate cancer. The preliminary results of the ERECT (EREctile Function Preservation for Prostate Cancer Radiation Therapy) trial were presented by University Medical Center Utrecht (UMC Utrecht, the Netherlands) clinicians at the 2025 European Society for Radiotherapy and Oncology (ESTRO) annual congress, May 2-6 in Vienna, Austria. The ERECT Trial is a sub-study of MOMENTUM, the MR-Linac Consortium's platform registry. It showed reduced incidence of erectile dysfunction (ED) and preserved erectile function up to 18 months using MR-guided radiotherapy (MRgRT) compared to conventional radiotherapy in patients with localized prostate cancer. In the study, researchers used Elekta Unity MR- Linac to treat 70 intermediate risk prostate cancer patients with a radiation dose of 36.25 Gy over five fractions. According to UMC Utrecht radiation oncologist and trial principal investor, Jochem van der Voort van Zyp, MD, PhD, Unity's pristine MR image quality not only enabled detailed visualization of the prostate, but also that of critical structures needed to achieve and maintain an erection. This anatomy includes the neurovascular bundle, internal pudendal arteries, corpora cavernosa and penile bulb. The endpoint of this preliminary analysis was the incidence of ED - as reported by patients - at six, 12- and 18-months post-treatment, compared to a control group that received the same dosage without neurovascular sparing. ED incidence was significantly lower in ERECT patients at all time points (six months: 6% vs. 21%, 12 months: 8.5% vs. 38%, 18 months: 16% vs. 36%). MRI is the gold standard for visualizing the prostate and surrounding structures in diagnostic radiology. Elekta Unity MR-Liac is the world's first and only device to combine a high-field MRI with a linear accelerator and enables clinicians to use MRI to guide radiation delivery to tumor targets and avoid surrounding structures. In addition, while treatment is ongoing, the system allows clinicians to non-invasively monitor the position of the target. If for example, if a prostate shifts due to motion of the bowels or bladder filling, the radiation treatment can be discontinued to avoid unnecessary radiation to surrounding normal tissues.공시 • Feb 27+ 1 more updateElekta AB (Publ) Announces Management ChangesElekta AB (publ) announced that Gustaf Salford, President and the Board of Directors, have decided that Gustaf will leave Elekta as of March 6, 2025. The Board of Directors has appointed Jonas Bolander, who has 23 years' experience at Elekta, as Acting President.Declared Dividend • Dec 30First half dividend of kr1.20 announcedShareholders will receive a dividend of kr1.20. Ex-date: 6th March 2025 Payment date: 12th March 2025 Dividend yield will be 25%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is not adequately covered by earnings (92% earnings payout ratio) nor is it covered by cash flows (157% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 1.7% to bring the payout ratio under control. EPS is expected to grow by 79% over the next 3 years, which is sufficient to bring the dividend into a sustainable range.공시 • Nov 27+ 2 more updatesElekta AB (publ) to Report Q2, 2026 Results on Nov 26, 2025Elekta AB (publ) announced that they will report Q2, 2026 results on Nov 26, 2025공시 • Nov 01Caroline Leksell Cooke Steps Down from Elekta AB's Board of DirectorsElekta AB announced that Caroline Leksell Cooke will step down from her role on the Board of Directors, effective November 1, 2024. This follows the earlier announcement that Caroline Leksell Cooke will assume the role of Senior Vice President and Head of Neuro Solutions, effective the same date, and in connection therewith leave her position as a board member.공시 • Sep 27Elekta AB Submits Elekta Evo to U.S. FDA for Premarket ApprovalElekta AB announced that its AI-powered adaptive CT-Linear Accelerator, Elekta Evo has been submitted and is now pending 510(k) premarket approval from the U.S. Food and Drug Administration (FDA) - this, less than a week after Evo received CE mark for sales and marketing in the European Union.Declared Dividend • Sep 08Dividend of kr1.20 announcedShareholders will receive a dividend of kr1.20. Ex-date: 6th March 2025 Payment date: 12th March 2025 Dividend yield will be 24%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (81% earnings payout ratio) but not covered by cash flows (111% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 63% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공시 • Sep 06Elekta AB (Publ) Approves Dividend, Payable on September 12, 2024, and on March 12, 2025, RespectivelyElekta AB (publ) at its AGM held on September 5, 2024, approved dividend corresponding to SEK 2.40 per share and that the remaining profits are carried forward. The dividend is to be divided into two payments of SEK 1.20 per payment. The first record day is September 9, 2024. The second record day is March 7, 2025. The dividend is expected to be paid out on September 12, 2024, and on March 12, 2025, respectively.Upcoming Dividend • Aug 30Upcoming dividend of kr1.20 per shareEligible shareholders must have bought the stock before 06 September 2024. Payment date: 12 September 2024. Payout ratio is on the higher end at 81%, and the cash payout ratio is above 100%. Trailing yield: 3.5%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (1.8%).Reported Earnings • Aug 29First quarter 2025 earnings released: EPS: kr0.18 (vs kr0.62 in 1Q 2024)First quarter 2025 results: EPS: kr0.18 (down from kr0.62 in 1Q 2024). Revenue: kr3.83b (flat on 1Q 2024). Net income: kr70.0m (down 71% from 1Q 2024). Profit margin: 1.8% (down from 6.2% in 1Q 2024). Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.New Risk • Aug 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (112% cash payout ratio). Share price has been volatile over the past 3 months (7.0% average weekly change).Declared Dividend • Aug 04Dividend of kr1.20 announcedShareholders will receive a dividend of kr1.20. Ex-date: 6th September 2024 Payment date: 12th September 2024 Dividend yield will be 26%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (70% earnings payout ratio) but not covered by cash flows (112% cash payout ratio). The dividend has increased by an average of 4.8% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 50% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Jul 07Full year 2024 earnings released: EPS: kr3.41 (vs kr2.47 in FY 2023)Full year 2024 results: EPS: kr3.41 (up from kr2.47 in FY 2023). Revenue: kr18.1b (up 7.4% from FY 2023). Net income: kr1.30b (up 38% from FY 2023). Profit margin: 7.2% (up from 5.6% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.공시 • Jul 06Elekta AB (publ) to Report Q4, 2025 Results on May 28, 2025Elekta AB (publ) announced that they will report Q4, 2025 results on May 28, 2025Recent Insider Transactions • Jun 11President & CEO recently bought €42k worth of stockOn the 7th of June, Gustaf Salford bought around 7k shares on-market at roughly €5.98 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Gustaf has been a buyer over the last 12 months, purchasing a net total of €84k worth in shares.공시 • Jun 06Elekta AB (publ) to Report Q3, 2025 Results on Feb 21, 2025Elekta AB (publ) announced that they will report Q3, 2025 results on Feb 21, 2025Reported Earnings • Jun 06Full year 2024 earnings released: EPS: kr3.41 (vs kr2.47 in FY 2023)Full year 2024 results: EPS: kr3.41 (up from kr2.47 in FY 2023). Revenue: kr18.1b (up 7.4% from FY 2023). Net income: kr1.30b (up 38% from FY 2023). Profit margin: 7.2% (up from 5.6% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.공시 • Mar 02Elekta AB (publ) Announces Resignation of Kelly Londy, Member of the BoardElekta AB announced that Kelly Londy, Member of the Board, will step down from her position and all board responsibilities, effective March 1, 2024. Ms. Londy has assumed a new senior executive role at another company, which will require her full attention. She has contributed significantly to Elekta’s Board and been greatly appreciated by her fellow board members. Elekta expresses its sincere gratitude to Ms. Londy for her dedicated service and wishes her continued success in her future role.Reported Earnings • Mar 01Third quarter 2024 earnings released: EPS: kr0.80 (vs kr0.56 in 3Q 2023)Third quarter 2024 results: EPS: kr0.80 (up from kr0.56 in 3Q 2023). Revenue: kr4.54b (up 4.6% from 3Q 2023). Net income: kr305.0m (up 41% from 3Q 2023). Profit margin: 6.7% (up from 5.0% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.공시 • Feb 29Elekta AB (publ) to Report Q2, 2025 Results on Nov 27, 2024Elekta AB (publ) announced that they will report Q2, 2025 results on Nov 27, 2024Upcoming Dividend • Feb 19Upcoming dividend of kr1.20 per shareEligible shareholders must have bought the stock before 26 February 2024. Payment date: 01 March 2024. Payout ratio is a comfortable 68% but the company is paying out more than the cash it is generating. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (5.1%). Higher than average of industry peers (1.6%).Reported Earnings • Dec 01Second quarter 2024 earnings released: EPS: kr0.90 (vs kr0.32 in 2Q 2023)Second quarter 2024 results: EPS: kr0.90 (up from kr0.32 in 2Q 2023). Revenue: kr4.73b (up 16% from 2Q 2023). Net income: kr344.0m (up 182% from 2Q 2023). Profit margin: 7.3% (up from 3.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings.공시 • Nov 30+ 1 more updateElekta AB (publ) to Report Fiscal Year 2024 Final Results on Jul 05, 2024Elekta AB (publ) announced that they will report fiscal year 2024 final results on Jul 05, 2024공시 • Nov 01Elekta AB (publ) Announces Composition of Nomination CommitteeElekta AB (publ) announced that Annual General Meeting on August 24, 2023, the Chairman of the Board has convened the Nomination Committee for the 2024 Annual General Meeting by contacting the company's shareholders in terms of votes, in addition to the shareholder or shareholders represented by the Chairman himself. The procedure is described in detail in the notice to the 2020 Annual General Meeting. The Nomination Committee consists of: Laurent Leksell, in his capacity as Chairman of the Board of Elekta and representing his own and related parties' holdings; Thomas Wuolikainen, appointed by the Fourth Swedish National Pension Fund; Katarina Hammar, appointed by Nordea Funds; Patrik Jönsson, appointed by SEB Funds; Jesper Bergström, appointed by Handelsbanken Funds.공시 • Oct 24Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD).Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD) on October 23, 2023. The intention is to complete the transaction during the second quarter of Elekta’s fiscal year 2023/24.공시 • Oct 13Elekta AB (publ), Annual General Meeting, Sep 05, 2024Elekta AB (publ), Annual General Meeting, Sep 05, 2024.Recent Insider Transactions • Sep 23Founder & Chairman recently sold €5.1m worth of stockOn the 20th of September, Laurent Leksell sold around 800k shares on-market at roughly €6.33 per share. This transaction amounted to 9.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Laurent's only on-market trade for the last 12 months.Reported Earnings • Aug 25First quarter 2024 earnings released: EPS: kr0.62 (vs kr0.16 in 1Q 2023)First quarter 2024 results: EPS: kr0.62 (up from kr0.16 in 1Q 2023). Revenue: kr3.83b (up 15% from 1Q 2023). Net income: kr238.0m (up 297% from 1Q 2023). Profit margin: 6.2% (up from 1.8% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 15% per year.공시 • Aug 25+ 1 more updateElekta AB (Publ) Approves Dividend, Payable on 31 August, 2023 and 1 March, 2024, RespectivelyElekta AB (publ) announced that at its AGM held on 24 August 2023, the Meeting resolved on a dividend corresponding to SEK 2.40 per share and that the remaining profits are carried forward. The dividend is to be divided into two payments of SEK 1.20 per payment. The first record day is 28 August, 2023. The second record day is 27 February, 2024. The dividend is expected to be paid out on 31 August, 2023 and on 1 March, 2024 respectively.Upcoming Dividend • Aug 18Upcoming dividend of kr1.20 per share at 3.1% yieldEligible shareholders must have bought the stock before 25 August 2023. Payment date: 31 August 2023. Payout ratio is on the higher end at 97%, and the cash payout ratio is above 100%. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (2.0%).Reported Earnings • Jul 09Full year 2023 earnings released: EPS: kr2.47 (vs kr3.02 in FY 2022)Full year 2023 results: EPS: kr2.47 (down from kr3.02 in FY 2022). Revenue: kr16.9b (up 16% from FY 2022). Net income: kr943.0m (down 18% from FY 2022). Profit margin: 5.6% (down from 7.9% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 6% per year.공시 • Jun 30Johan Malmquist Declines Re-Election as Director of Elekta AB (Publ)Elekta AB (publ) announced that 2023 Annual General Meeting to held on 24 August 2023, Johan Malmquist has declined re-election as director of the company.Buying Opportunity • May 31Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 1.8%. The fair value is estimated to be €8.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has declined by 11%. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings is also forecast to grow by 23% per annum over the same time period.공시 • May 26+ 2 more updatesElekta AB (publ) to Report Q3, 2024 Results on Feb 09, 2024Elekta AB (publ) announced that they will report Q3, 2024 results on Feb 09, 2024Reported Earnings • May 26Full year 2023 earnings released: EPS: kr2.47 (vs kr3.02 in FY 2022)Full year 2023 results: EPS: kr2.47 (down from kr3.02 in FY 2022). Revenue: kr16.9b (up 16% from FY 2022). Net income: kr943.0m (down 18% from FY 2022). Profit margin: 5.6% (down from 7.9% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 9% per year.공시 • May 25+ 1 more updateElekta AB (publ) Provides Earnings Guidance for the Fiscal Year from 2022-2023 to 2024-2025Elekta AB (publ) provided earnings guidance for the fiscal year from 2022-2023 to 2024-2025. For the period, the company expects net sales CAGR of above 7%.공시 • May 13Elekta AB (Publ) Announces the Launch of the First Phase of Elekta ONEElekta AB (publ) is excited to announced the launch of the first phase of Elekta ONE, its most comprehensive and advanced software portfolio for oncology departments and clinics, including radiation therapy planning, comprehensive treatment management, and delivery. It brings all Elekta software products, solutions and services under one umbrella providing all users with one unified software experience. Previously, many cancer clinics have wrestled with stand-alone, closed systems, each with a different purpose. The result has been an unfavorable user experience and steep learning curve, adding pressure to an already strained resource: the clinical team. Elekta ONE aims to improve efficiency in the clinic by as much as 50%, eventually through smarter workflows, increased automation, and by learning from every patient treated. Its workflow-driven approach and deep integration between applications allows information to flow freely, giving clinicians a seamless user experience.Buying Opportunity • May 09Now 21% undervaluedOver the last 90 days, the stock is up 13%. The fair value is estimated to be €9.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 9.7%. For the next 3 years, revenue is forecast to grow by 7.4% per annum. Earnings is also forecast to grow by 23% per annum over the same time period.Reported Earnings • Feb 26Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr4.34b (up 20% from 3Q 2022). Net income: kr216.0m (down 5.7% from 3Q 2022). Profit margin: 5.0% (down from 6.4% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 8% per year.Valuation Update With 7 Day Price Move • Feb 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €7.73, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €12.31 per share.Upcoming Dividend • Feb 17Upcoming dividend of kr1.20 per share at 3.1% yieldEligible shareholders must have bought the stock before 24 February 2023. Payment date: 02 March 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (4.6%). Higher than average of industry peers (1.7%).공시 • Feb 14Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter.Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter on February 13, 2023. The first quarter of Elekta’s fiscal year 2023-2024.공시 • Dec 13First Ever Patient Treated for Pancreatic Cancer with New Advanced Radiotherapy Motion Management Using Elekta Unity MR-LinacElekta AB (publ) announced that UTRECHT - A milestone was reached in radiation therapy last week as the first patients completed their full course of radiation therapy treatment with Elekta (EKTA-B.ST) Unity MR-Linac using Comprehensive Motion Management (CMM) with True Tracking and automatic gating functionalities. A patient with pancreatic cancer was treated at University Medical Center (UMC) Utrecht using Unity's CMM developments, which can continuously calculate the movement of the tumor and correct for it automatically. This first ever treatment delivery using CMM went smoothly and did not increase the total treatment time per fraction. The beam wasautomatically turned on when the patient was in the exhale phase of breathing, so they were not required to hold their breath for extended periods, according to Dr. Martijn Intven, a radiation oncologist at UMC Utrecht. With automatic gating, supported by Elekta's unique True Tracking algorithms, the radiation beam is automatically turned off when the tumor moves outside of the beam, ensuring treatment is always focused on the target. For the first time ever in radiotherapy, Elekta Unity's True Tracking provides continuous tracking of the 3D position of a target anywhere in the body, non-invasively and without surrogates. In addition, CMM offers rapid compensation for sustained intrafraction drift: realigning the beam with the new position of the target without the need to re-acquire a 3D image. UMC Utrecht was Elekta's initial research partner in the development of Elekta Unity, aproject that has extended over two decades. During this time, clinicians at UMC have helped pioneer radiation treatment that responds to movement of tumors during delivery.Reported Earnings • Nov 25Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr4.08b (up 10% from 2Q 2022). Net income: kr122.0m (down 68% from 2Q 2022). Profit margin: 3.0% (down from 10% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.공시 • Nov 24Elekta AB (publ), Annual General Meeting, Aug 24, 2023Elekta AB (publ), Annual General Meeting, Aug 24, 2023.공시 • Nov 18Swedish and Jordanian Royalty Inaugurate Elekta AB (publ) Radiation Therapy Devices for Cancer and Brain DiseaseDignitaries from Sweden and Jordan attended the inauguration of two of Elekta's cancer care technologies, including an advanced linear accelerator used to deliver radiation to treat people with cancer and a Leksell Gamma Knife radiosurgery system, which is used to treat a range of neurosurgical and oncological brain indications. The ceremony was held on November 16 at King Hussein Cancer Center together with King Hussein Cancer Foundation in Amman. Representing Elekta, Caroline Leksell Cooke, Member of Elekta's Board of Directors and granddaughter of Professor Lars Leksell, inventor of the Gamma Knife, spoke of her pride in the company's collaboration with health care facilities in Jordan and support to improve the lives of some of the 11,500 people diagnosed with cancer each year. The first Elekta linac and Gamma Knife were installed in Jordan in 2005, with successive upgrades and new technology since. Today, a wide spectrum of cancer is managed with the country's 15 Elekta linacs, two Gamma Knife systems, and brachytherapy solutions. Their Majesties the King and Queen of Sweden, Her Royal Highness Princess Ghida Talal, who is Chairperson of KHCC, His Royal Highness Prince Talal bin Muhammad, Caroline Leksell Cooke, the Swedish Ambassador to Jordan H.E. Alexandra Rydmark, and Dr. Asem Mansour KHCC General Director, were among those attending the event. The inauguration ceremony was part of a three-day state visit by Sweden's King Carl XVI Gustaf and Queen Silvia, together with Sweden's Minister of Foreign Affairs, H.E.Tobias Billström. During their visit, they will also pay tribute to the 40th anniversary of Sweden's diplomatic presence in Jordan.Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Director Kelly Londy was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Oct 28Elekta AB (publ) Announces Elekta Esprit Receives FDA 510(k) ClearanceElekta AB (publ) announced that Elekta Esprit, a new Leksell Gamma Knife® radiosurgery platform, received FDA 510(k) clearance. This milestone makes the system available to clinicians and people with brain disease in the U.S., as well as opening the door to other countries where FDA approval is recognized. Leksell Gamma Knife has been designed as a gentler alternative to open surgery and conventional radiotherapy. It can target the smallest and most challenging intracranial tumors and lesions with minimal effect on healthy tissue. This vital precision safeguards motor, sensory and neurocognitive function to help protect the mind and the person. With a variety of innovations now available in a single platform, Esprit continues to offer clinicians the option of frameless or frame-based workflows with a frame that provides superior visualization. Remote accessibility and collaboration tools for the treatment team are designed to meet the needs of changing environments. Esprit provides the accuracy to treat even the most challenging targets while delivering a gentler more personalized approach to radiosurgery. Leksell Gamma Knife has over 50 years of clinical evidence and remains the gold standard of intracranial radiosurgery. The U.S. has the largest installed base of Gamma Knife systems, whose users have contributed to driving the standard of care forward. Continuous advances in its design have resulted in extremely fast automated treatment planning for clinicians, and Esprit is ideal for safely treating a broad range of indications, including multiple metastases, arteriovenous malformations, trigeminal neuralgia and vestibular schwannoma.공시 • Oct 26Elekta Unity Demonstrates Promising Quality of Life Outcomes for Pancreas and Prostate Cancers At Astro Annual MeetingElekta announced two new reports from the MOMENTUM Study highlighting the clinical impact of Elekta Unity MR-Linac in treating pancreas and prostate cancers. The abstracts were presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting, in San Antonio, Texas. These reports add to a growing body of evidence showing that enhanced precision radiotherapy using MR-guided on-line adaptation may improve outcomes in both pancreas and prostate cancers, two common treatment indications for radiotherapy. Elekta Unity is the world’s first and only MR-Linac to unite diagnostic quality high field (1.5T) MRI with a linear accelerator to deliver unprecedented visibility and precision, thus enabling personalized radiotherapy. The MOMENTUM Study is the largest prospective international registry of high field MR-guided therapy, currently enrolling patients from 15 major cancer centers in North America, Europe and Australia. In the study of pancreas tumors, which are historically treatment resistant, 80 patients treated with an ablative radiation dose using MR-guided online adaption were enrolled and surveyed using standardized quality-of-life questionnaires. Patients reported limited adverse effects and stable global health status out to three months. Importantly, 67% of patients were alive one year after the end of treatment. In the study of prostate cancers, 218 patients were enrolled and followed with standardized quality-of-life questionnaires. Approximately half of the patients were treated using both MR-guidance and on-line adaptation functionality on Elekta Unity while the remaining half were treated using only MR-guidance without on-line adaptation. As expected, investigators observed a decline in quality-of-life scores three months after the end of treatment in the cohort treated with MR-guidance alone. However, no significant decline in quality of life was observed in the cohort of prostate cancers treated using both MR-guidance and on-line adaptation.공시 • Sep 19Elekta AB (publ)(OM:EKTA B) dropped from FTSE All-World Index (USD)Elekta AB (publ)(OM:EKTA B) dropped from FTSE All-World Index (USD)공시 • Aug 26+ 1 more updateElekta AB (publ) Elects Kelly Londy as a DirectorElekta AB (publ) announced that Kelly Londy was elected as a new Director at its Annual General Meeting held on 25 August 2022.Reported Earnings • Aug 26First quarter 2023 earnings released: EPS: kr0.16 (vs kr0.33 in 1Q 2022)First quarter 2023 results: EPS: kr0.16 (down from kr0.33 in 1Q 2022). Revenue: kr3.33b (up 11% from 1Q 2022). Net income: kr60.0m (down 53% from 1Q 2022). Profit margin: 1.8% (down from 4.2% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 8.5%, compared to a 7.8% growth forecast for the Medical Equipment industry in Germany.Upcoming Dividend • Aug 19Upcoming dividend of kr1.20 per shareEligible shareholders must have bought the stock before 26 August 2022. Payment date: 01 September 2022. Payout ratio is on the higher end at 79%, and the cash payout ratio is above 100%. Trailing yield: 3.3%. Lower than top quartile of German dividend payers (4.5%). Higher than average of industry peers (1.2%).Reported Earnings • Jul 13Full year 2022 earnings released: EPS: kr3.02 (vs kr3.28 in FY 2021)Full year 2022 results: EPS: kr3.02 (down from kr3.28 in FY 2021). Revenue: kr14.5b (up 5.7% from FY 2021). Net income: kr1.15b (down 8.0% from FY 2021). Profit margin: 7.9% (down from 9.1% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 9.4%, compared to a 8.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.공시 • Jul 09+ 1 more updateElekta AB (publ) to Report Fiscal Year 2023 Results on May 25, 2023Elekta AB (publ) announced that they will report fiscal year 2023 results on May 25, 2023Reported Earnings • May 26Full year 2022 earnings released: EPS: kr3.02 (vs kr3.28 in FY 2021)Full year 2022 results: EPS: kr3.02 (down from kr3.28 in FY 2021). Revenue: kr14.5b (up 5.7% from FY 2021). Net income: kr1.15b (down 8.0% from FY 2021). Profit margin: 7.9% (down from 9.1% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 8.4%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.공시 • May 26Elekta AB (Publ) Proposes Dividend for the Fiscal Year 2021/22The Board of Directors of Elekta AB (publ) proposed a dividend of SEK 2.40 (SEK 2.20) per share (paid in two installments) for the fiscal year 2021/22.공시 • May 08Elekta Launches New Radiosurgery System: Elekta EspritElekta AB (publ) has evolved radiosurgery to an unprecedented level with the launch of Elekta Esprit. This latest and most advanced system will offer significantly faster automated treatment planning for clinicians, more personalized and patient-friendly treatments, and a degree of precision able to protect the mind and the person. With a variety of innovations now available in a single platform, Esprit offers clinicians superior visualization, as well as remote accessibility and collaboration tools for the treatment team. And it provides the accuracy to treat even the most challenging targets while delivering a gentler more personalized approach to radiosurgery.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Director Cecilia Wikström was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Apr 26+ 2 more updatesElekta AB (publ) to Report Fiscal Year 2022 Final Results on Jul 08, 2022Elekta AB (publ) announced that they will report fiscal year 2022 final results on Jul 08, 2022Recent Insider Transactions • Mar 10President of Brachy Solutions recently bought €30k worth of stockOn the 2nd of March, John Lapré bought around 4k shares on-market at roughly €7.41 per share. In the last 3 months, there was an even bigger purchase from another insider worth €145k. Insiders have collectively bought €2.1m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Mar 04Insider recently bought €49k worth of stockOn the 24th of February, Verena Schiller bought around 6k shares on-market at roughly €7.58 per share. In the last 3 months, there was an even bigger purchase from another insider worth €145k. Insiders have collectively bought €2.1m more in shares than they have sold in the last 12 months.Reported Earnings • Feb 25Third quarter 2022 earnings: Revenues in line with analyst expectationsThird quarter 2022 results: Revenue: kr3.60b (flat on 3Q 2021). Net income: kr229.0m (down 29% from 3Q 2021). Profit margin: 6.4% (down from 9.0% in 3Q 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 11%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.공시 • Feb 24Elekta AB (publ), Annual General Meeting, Aug 25, 2022Elekta AB (publ), Annual General Meeting, Aug 25, 2022.Valuation Update With 7 Day Price Move • Feb 19Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €7.79, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 29x in the Medical Equipment industry in Germany. Total loss to shareholders of 32% over the past three years.Upcoming Dividend • Feb 18Upcoming dividend of kr1.10 per shareEligible shareholders must have bought the stock before 25 February 2022. Payment date: 03 March 2022. Payout ratio is a comfortable 72% and the cash payout ratio is 80%. Trailing yield: 2.6%. Lower than top quartile of German dividend payers (3.3%). Higher than average of industry peers (1.1%).Recent Insider Transactions • Dec 18President & CEO recently bought €145k worth of stockOn the 16th of December, Gustaf Salford bought around 14k shares on-market at roughly €10.38 per share. In the last 3 months, there was an even bigger purchase from another insider worth €4.8m. Gustaf has been a buyer over the last 12 months, purchasing a net total of €301k worth in shares.이익 및 매출 성장 예측DB:EJXB - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수4/30/202918,8941,7711,8432,757114/30/202818,1021,6051,7412,769134/30/202717,3851,4261,4752,384144/30/202616,718-5191,3922,464N/A1/31/202617,111-401,4992,652N/A10/31/202517,5672921,9753,214N/A7/31/202517,8372741,5853,033N/A4/30/202518,0162371,0562,626N/A1/31/202517,8821,0386822,375N/A10/31/202417,7241,0025832,352N/A7/31/202418,1161,1348242,519N/A4/30/202418,1191,3028172,461N/A1/31/202418,2211,4331,5163,135N/A10/31/202318,0211,3447232,289N/A7/31/202317,3701,121961,611N/A4/30/202316,8699434001,964N/A1/31/202315,984813-5511,013N/A10/31/202215,249826-2011,361N/A7/31/202214,8661,0872001,741N/A4/30/202214,5481,1544501,858N/A1/31/202213,9761,0796481,933N/A10/31/202113,9551,1729582,049N/A7/31/202113,7911,1651,3022,259N/A4/30/202113,7631,2541,7062,551N/A1/31/202114,1041,3211,7392,680N/A10/31/202014,1791,3071,0881,970N/A7/31/202014,3541,1531,0441,854N/A4/30/202014,6011,0842521,014N/A1/31/202014,6801,212N/A1,318N/A10/31/201914,3431,115N/A1,281N/A7/31/201913,9641,179N/A1,373N/A4/30/201913,5551,198N/A1,621N/A1/31/201912,8771,164N/A1,307N/A10/31/201812,3151,295N/A2,056N/A7/31/201811,8881,315N/A1,947N/A4/30/201811,5731,348N/A2,404N/A1/31/201811,879939N/A2,393N/A10/31/201711,795639N/A2,095N/A7/31/201711,326389N/A2,034N/A4/30/201710,704125N/A1,819N/A1/31/201710,596108N/A1,442N/A10/31/201610,47070N/A1,375N/A7/31/201610,864203N/A1,380N/A4/30/201611,221137N/A1,170N/A1/31/201611,469402N/A1,989N/A10/31/201511,474548N/A1,862N/A7/31/201511,213558N/A1,952N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: EJXB 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(1.9%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: EJXB (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: EJXB 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: EJXB 의 수익(연간 4.2%)이 German 시장(연간 6.5%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: EJXB 의 수익(연간 4.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: EJXB의 자본 수익률은 3년 후 20.2%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/27 18:55종가2026/06/26 00:00수익2026/04/30연간 수익2026/04/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Elekta AB (publ)는 27명의 분석가가 다루고 있습니다. 이 중 14명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullABG Sundal CollierAlexander KlebanBarclaysSally TaylorBarclays24명의 분석가 더 보기
공시 • May 28+ 2 more updatesElekta AB (publ) Provides Earnings Guidance for the Fiscal Year 2026/2027Elekta AB (publ) provided earnings guidance for the fiscal year 2026/2027. For the year, The company expects net sales in constant currency to increase year over year, with an improvement in the EBIT margin.
공시 • Aug 28Elekta AB (publ) Provides Earnings Guidance for the Second Quarter 2025-2026 and Reiterates Earnings Guidance for the Year 2025-2026Elekta AB (publ) provided earnings guidance for the second quarter 2025-2026 and reiterated earnings guidance for the year 2025-2026. The company expects net sales for second quarter to be negatively impacted by a continued weak US development as well as a negative effect from last year's low order intake in China. However, The company expects sales in China to start to recover during the second half of 2025/26. Furthermore, company expect a continuous negative impact on earnings from FX at current exchange rates and from tariffs in second quarter. The company reiterates full year 2025-2026 outlook, where the company expects net sales in constant currency to grow year-over-year.
공시 • May 25+ 1 more updateElekta AB (publ) Provides Earnings Guidance for the Fiscal Year from 2022-2023 to 2024-2025Elekta AB (publ) provided earnings guidance for the fiscal year from 2022-2023 to 2024-2025. For the period, the company expects net sales CAGR of above 7%.
Declared Dividend • May 31Final dividend of kr1.20 announcedShareholders will receive a dividend of kr1.20. Ex-date: 4th September 2026 Payment date: 10th September 2026 Dividend yield will be 27%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (66% cash payout ratio). The dividend has increased by an average of 17% per year over the past 10 years. However, payments have been volatile during that time.
Reported Earnings • May 28Full year 2026 earnings released: kr1.36 loss per share (vs kr0.62 profit in FY 2025)Full year 2026 results: kr1.36 loss per share (down from kr0.62 profit in FY 2025). Revenue: kr16.7b (down 7.2% from FY 2025). Net loss: kr519.0m (down 319% from profit in FY 2025). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance.
공시 • May 28+ 2 more updatesElekta AB (publ) Provides Earnings Guidance for the Fiscal Year 2026/2027Elekta AB (publ) provided earnings guidance for the fiscal year 2026/2027. For the year, The company expects net sales in constant currency to increase year over year, with an improvement in the EBIT margin.
Board Change • May 21High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Jan De Witte was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공시 • May 19Elekta AB (publ) to Report Fiscal Year 2026 Final Results on Jul 03, 2026Elekta AB (publ) announced that they will report fiscal year 2026 final results at 9:00 AM, Central European Standard Time on Jul 03, 2026
공시 • Mar 05+ 1 more updateElekta AB (publ) to Report Q2, 2027 Results on Nov 25, 2026Elekta AB (publ) announced that they will report Q2, 2027 results on Nov 25, 2026
공시 • Feb 26Elekta AB (publ), Annual General Meeting, Sep 03, 2026Elekta AB (publ), Annual General Meeting, Sep 03, 2026.
공시 • Jan 23Elekta AB Appoints Tomas Eliasson as Vice Chair of the Board, Effective January 23, 2026Elekta AB has established the role of Vice Chair of the Board and appointed Tomas Eliasson to this position, effective January 23, 2026. Tomas Eliasson has been a member of Elekta’s Board of Directors since 2023 and the Chair of its Audit Committee since 2024. He brings extensive experience from senior leadership and board roles in global industrial and technology-driven companies. His background includes deep expertise in finance, governance and strategy, supporting Elekta’s continued focus on long-term value creation.
공시 • Jan 16Elekta Receives FDA 510(K) Clearance for Elekta Evo Linear AcceleratorElekta announced that its Elekta Evo CT-Linac has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This milestone makes the system available to radiation oncology professionals in the United States. When delivering radiation therapy, clinicians require high-quality images that allow them to identify tumors and organs-at-risk. Evo addresses this with Iris®? high-definition, AI-enhanced imaging, which allows physicians to see target areas and critical structures for every fraction with greater clarity. In Europe and other countries, Elekta Evo continues to gain traction, setting new benchmarks in radiation therapy as more clinics adopt its innovative treatment capabilities.
공시 • Sep 04+ 1 more updateElekta AB (Publ) Elects Jan De Witte as DirectorElekta AB (publ) at its AGM held on September 4, 2025 approved to elect Jan De Witte, as Director for the period until the end of the next Annual General Meeting.
공시 • Aug 28Elekta AB (publ) Provides Earnings Guidance for the Second Quarter 2025-2026 and Reiterates Earnings Guidance for the Year 2025-2026Elekta AB (publ) provided earnings guidance for the second quarter 2025-2026 and reiterated earnings guidance for the year 2025-2026. The company expects net sales for second quarter to be negatively impacted by a continued weak US development as well as a negative effect from last year's low order intake in China. However, The company expects sales in China to start to recover during the second half of 2025/26. Furthermore, company expect a continuous negative impact on earnings from FX at current exchange rates and from tariffs in second quarter. The company reiterates full year 2025-2026 outlook, where the company expects net sales in constant currency to grow year-over-year.
공시 • May 29Elekta AB (publ), Annual General Meeting, Sep 04, 2025Elekta AB (publ), Annual General Meeting, Sep 04, 2025.
공시 • May 28+ 1 more updateElekta AB (publ) Proposes Dividend for the Fiscal Year 2024/25The Board of Directors of Elekta AB (publ) proposed a dividend of SEK 2.40 (SEK 2.40) per share (paid in two installments) for 2024/25 amounting to SEK 917 million.
공시 • May 19+ 1 more updateElekta AB (publ) to Report Q3, 2026 Results on Mar 05, 2026Elekta AB (publ) announced that they will report Q3, 2026 results on Mar 05, 2026
공시 • May 05Elekta Announces Use of Its 1.5T Elekta Unity MR-LinacElekta announced that use of its 1.5T Elekta Unity MR-Linac can enable doctors to reduce the radiation dose to key structures responsible for erection among men being treated for prostate cancer. The preliminary results of the ERECT (EREctile Function Preservation for Prostate Cancer Radiation Therapy) trial were presented by University Medical Center Utrecht (UMC Utrecht, the Netherlands) clinicians at the 2025 European Society for Radiotherapy and Oncology (ESTRO) annual congress, May 2-6 in Vienna, Austria. The ERECT Trial is a sub-study of MOMENTUM, the MR-Linac Consortium's platform registry. It showed reduced incidence of erectile dysfunction (ED) and preserved erectile function up to 18 months using MR-guided radiotherapy (MRgRT) compared to conventional radiotherapy in patients with localized prostate cancer. In the study, researchers used Elekta Unity MR- Linac to treat 70 intermediate risk prostate cancer patients with a radiation dose of 36.25 Gy over five fractions. According to UMC Utrecht radiation oncologist and trial principal investor, Jochem van der Voort van Zyp, MD, PhD, Unity's pristine MR image quality not only enabled detailed visualization of the prostate, but also that of critical structures needed to achieve and maintain an erection. This anatomy includes the neurovascular bundle, internal pudendal arteries, corpora cavernosa and penile bulb. The endpoint of this preliminary analysis was the incidence of ED - as reported by patients - at six, 12- and 18-months post-treatment, compared to a control group that received the same dosage without neurovascular sparing. ED incidence was significantly lower in ERECT patients at all time points (six months: 6% vs. 21%, 12 months: 8.5% vs. 38%, 18 months: 16% vs. 36%). MRI is the gold standard for visualizing the prostate and surrounding structures in diagnostic radiology. Elekta Unity MR-Liac is the world's first and only device to combine a high-field MRI with a linear accelerator and enables clinicians to use MRI to guide radiation delivery to tumor targets and avoid surrounding structures. In addition, while treatment is ongoing, the system allows clinicians to non-invasively monitor the position of the target. If for example, if a prostate shifts due to motion of the bowels or bladder filling, the radiation treatment can be discontinued to avoid unnecessary radiation to surrounding normal tissues.
공시 • Feb 27+ 1 more updateElekta AB (Publ) Announces Management ChangesElekta AB (publ) announced that Gustaf Salford, President and the Board of Directors, have decided that Gustaf will leave Elekta as of March 6, 2025. The Board of Directors has appointed Jonas Bolander, who has 23 years' experience at Elekta, as Acting President.
Declared Dividend • Dec 30First half dividend of kr1.20 announcedShareholders will receive a dividend of kr1.20. Ex-date: 6th March 2025 Payment date: 12th March 2025 Dividend yield will be 25%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is not adequately covered by earnings (92% earnings payout ratio) nor is it covered by cash flows (157% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 1.7% to bring the payout ratio under control. EPS is expected to grow by 79% over the next 3 years, which is sufficient to bring the dividend into a sustainable range.
공시 • Nov 27+ 2 more updatesElekta AB (publ) to Report Q2, 2026 Results on Nov 26, 2025Elekta AB (publ) announced that they will report Q2, 2026 results on Nov 26, 2025
공시 • Nov 01Caroline Leksell Cooke Steps Down from Elekta AB's Board of DirectorsElekta AB announced that Caroline Leksell Cooke will step down from her role on the Board of Directors, effective November 1, 2024. This follows the earlier announcement that Caroline Leksell Cooke will assume the role of Senior Vice President and Head of Neuro Solutions, effective the same date, and in connection therewith leave her position as a board member.
공시 • Sep 27Elekta AB Submits Elekta Evo to U.S. FDA for Premarket ApprovalElekta AB announced that its AI-powered adaptive CT-Linear Accelerator, Elekta Evo has been submitted and is now pending 510(k) premarket approval from the U.S. Food and Drug Administration (FDA) - this, less than a week after Evo received CE mark for sales and marketing in the European Union.
Declared Dividend • Sep 08Dividend of kr1.20 announcedShareholders will receive a dividend of kr1.20. Ex-date: 6th March 2025 Payment date: 12th March 2025 Dividend yield will be 24%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (81% earnings payout ratio) but not covered by cash flows (111% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 63% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공시 • Sep 06Elekta AB (Publ) Approves Dividend, Payable on September 12, 2024, and on March 12, 2025, RespectivelyElekta AB (publ) at its AGM held on September 5, 2024, approved dividend corresponding to SEK 2.40 per share and that the remaining profits are carried forward. The dividend is to be divided into two payments of SEK 1.20 per payment. The first record day is September 9, 2024. The second record day is March 7, 2025. The dividend is expected to be paid out on September 12, 2024, and on March 12, 2025, respectively.
Upcoming Dividend • Aug 30Upcoming dividend of kr1.20 per shareEligible shareholders must have bought the stock before 06 September 2024. Payment date: 12 September 2024. Payout ratio is on the higher end at 81%, and the cash payout ratio is above 100%. Trailing yield: 3.5%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (1.8%).
Reported Earnings • Aug 29First quarter 2025 earnings released: EPS: kr0.18 (vs kr0.62 in 1Q 2024)First quarter 2025 results: EPS: kr0.18 (down from kr0.62 in 1Q 2024). Revenue: kr3.83b (flat on 1Q 2024). Net income: kr70.0m (down 71% from 1Q 2024). Profit margin: 1.8% (down from 6.2% in 1Q 2024). Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
New Risk • Aug 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (112% cash payout ratio). Share price has been volatile over the past 3 months (7.0% average weekly change).
Declared Dividend • Aug 04Dividend of kr1.20 announcedShareholders will receive a dividend of kr1.20. Ex-date: 6th September 2024 Payment date: 12th September 2024 Dividend yield will be 26%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (70% earnings payout ratio) but not covered by cash flows (112% cash payout ratio). The dividend has increased by an average of 4.8% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 50% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Jul 07Full year 2024 earnings released: EPS: kr3.41 (vs kr2.47 in FY 2023)Full year 2024 results: EPS: kr3.41 (up from kr2.47 in FY 2023). Revenue: kr18.1b (up 7.4% from FY 2023). Net income: kr1.30b (up 38% from FY 2023). Profit margin: 7.2% (up from 5.6% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
공시 • Jul 06Elekta AB (publ) to Report Q4, 2025 Results on May 28, 2025Elekta AB (publ) announced that they will report Q4, 2025 results on May 28, 2025
Recent Insider Transactions • Jun 11President & CEO recently bought €42k worth of stockOn the 7th of June, Gustaf Salford bought around 7k shares on-market at roughly €5.98 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Gustaf has been a buyer over the last 12 months, purchasing a net total of €84k worth in shares.
공시 • Jun 06Elekta AB (publ) to Report Q3, 2025 Results on Feb 21, 2025Elekta AB (publ) announced that they will report Q3, 2025 results on Feb 21, 2025
Reported Earnings • Jun 06Full year 2024 earnings released: EPS: kr3.41 (vs kr2.47 in FY 2023)Full year 2024 results: EPS: kr3.41 (up from kr2.47 in FY 2023). Revenue: kr18.1b (up 7.4% from FY 2023). Net income: kr1.30b (up 38% from FY 2023). Profit margin: 7.2% (up from 5.6% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
공시 • Mar 02Elekta AB (publ) Announces Resignation of Kelly Londy, Member of the BoardElekta AB announced that Kelly Londy, Member of the Board, will step down from her position and all board responsibilities, effective March 1, 2024. Ms. Londy has assumed a new senior executive role at another company, which will require her full attention. She has contributed significantly to Elekta’s Board and been greatly appreciated by her fellow board members. Elekta expresses its sincere gratitude to Ms. Londy for her dedicated service and wishes her continued success in her future role.
Reported Earnings • Mar 01Third quarter 2024 earnings released: EPS: kr0.80 (vs kr0.56 in 3Q 2023)Third quarter 2024 results: EPS: kr0.80 (up from kr0.56 in 3Q 2023). Revenue: kr4.54b (up 4.6% from 3Q 2023). Net income: kr305.0m (up 41% from 3Q 2023). Profit margin: 6.7% (up from 5.0% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.
공시 • Feb 29Elekta AB (publ) to Report Q2, 2025 Results on Nov 27, 2024Elekta AB (publ) announced that they will report Q2, 2025 results on Nov 27, 2024
Upcoming Dividend • Feb 19Upcoming dividend of kr1.20 per shareEligible shareholders must have bought the stock before 26 February 2024. Payment date: 01 March 2024. Payout ratio is a comfortable 68% but the company is paying out more than the cash it is generating. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (5.1%). Higher than average of industry peers (1.6%).
Reported Earnings • Dec 01Second quarter 2024 earnings released: EPS: kr0.90 (vs kr0.32 in 2Q 2023)Second quarter 2024 results: EPS: kr0.90 (up from kr0.32 in 2Q 2023). Revenue: kr4.73b (up 16% from 2Q 2023). Net income: kr344.0m (up 182% from 2Q 2023). Profit margin: 7.3% (up from 3.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings.
공시 • Nov 30+ 1 more updateElekta AB (publ) to Report Fiscal Year 2024 Final Results on Jul 05, 2024Elekta AB (publ) announced that they will report fiscal year 2024 final results on Jul 05, 2024
공시 • Nov 01Elekta AB (publ) Announces Composition of Nomination CommitteeElekta AB (publ) announced that Annual General Meeting on August 24, 2023, the Chairman of the Board has convened the Nomination Committee for the 2024 Annual General Meeting by contacting the company's shareholders in terms of votes, in addition to the shareholder or shareholders represented by the Chairman himself. The procedure is described in detail in the notice to the 2020 Annual General Meeting. The Nomination Committee consists of: Laurent Leksell, in his capacity as Chairman of the Board of Elekta and representing his own and related parties' holdings; Thomas Wuolikainen, appointed by the Fourth Swedish National Pension Fund; Katarina Hammar, appointed by Nordea Funds; Patrik Jönsson, appointed by SEB Funds; Jesper Bergström, appointed by Handelsbanken Funds.
공시 • Oct 24Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD).Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD) on October 23, 2023. The intention is to complete the transaction during the second quarter of Elekta’s fiscal year 2023/24.
공시 • Oct 13Elekta AB (publ), Annual General Meeting, Sep 05, 2024Elekta AB (publ), Annual General Meeting, Sep 05, 2024.
Recent Insider Transactions • Sep 23Founder & Chairman recently sold €5.1m worth of stockOn the 20th of September, Laurent Leksell sold around 800k shares on-market at roughly €6.33 per share. This transaction amounted to 9.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Laurent's only on-market trade for the last 12 months.
Reported Earnings • Aug 25First quarter 2024 earnings released: EPS: kr0.62 (vs kr0.16 in 1Q 2023)First quarter 2024 results: EPS: kr0.62 (up from kr0.16 in 1Q 2023). Revenue: kr3.83b (up 15% from 1Q 2023). Net income: kr238.0m (up 297% from 1Q 2023). Profit margin: 6.2% (up from 1.8% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 15% per year.
공시 • Aug 25+ 1 more updateElekta AB (Publ) Approves Dividend, Payable on 31 August, 2023 and 1 March, 2024, RespectivelyElekta AB (publ) announced that at its AGM held on 24 August 2023, the Meeting resolved on a dividend corresponding to SEK 2.40 per share and that the remaining profits are carried forward. The dividend is to be divided into two payments of SEK 1.20 per payment. The first record day is 28 August, 2023. The second record day is 27 February, 2024. The dividend is expected to be paid out on 31 August, 2023 and on 1 March, 2024 respectively.
Upcoming Dividend • Aug 18Upcoming dividend of kr1.20 per share at 3.1% yieldEligible shareholders must have bought the stock before 25 August 2023. Payment date: 31 August 2023. Payout ratio is on the higher end at 97%, and the cash payout ratio is above 100%. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (2.0%).
Reported Earnings • Jul 09Full year 2023 earnings released: EPS: kr2.47 (vs kr3.02 in FY 2022)Full year 2023 results: EPS: kr2.47 (down from kr3.02 in FY 2022). Revenue: kr16.9b (up 16% from FY 2022). Net income: kr943.0m (down 18% from FY 2022). Profit margin: 5.6% (down from 7.9% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 6% per year.
공시 • Jun 30Johan Malmquist Declines Re-Election as Director of Elekta AB (Publ)Elekta AB (publ) announced that 2023 Annual General Meeting to held on 24 August 2023, Johan Malmquist has declined re-election as director of the company.
Buying Opportunity • May 31Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 1.8%. The fair value is estimated to be €8.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has declined by 11%. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings is also forecast to grow by 23% per annum over the same time period.
공시 • May 26+ 2 more updatesElekta AB (publ) to Report Q3, 2024 Results on Feb 09, 2024Elekta AB (publ) announced that they will report Q3, 2024 results on Feb 09, 2024
Reported Earnings • May 26Full year 2023 earnings released: EPS: kr2.47 (vs kr3.02 in FY 2022)Full year 2023 results: EPS: kr2.47 (down from kr3.02 in FY 2022). Revenue: kr16.9b (up 16% from FY 2022). Net income: kr943.0m (down 18% from FY 2022). Profit margin: 5.6% (down from 7.9% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 9% per year.
공시 • May 25+ 1 more updateElekta AB (publ) Provides Earnings Guidance for the Fiscal Year from 2022-2023 to 2024-2025Elekta AB (publ) provided earnings guidance for the fiscal year from 2022-2023 to 2024-2025. For the period, the company expects net sales CAGR of above 7%.
공시 • May 13Elekta AB (Publ) Announces the Launch of the First Phase of Elekta ONEElekta AB (publ) is excited to announced the launch of the first phase of Elekta ONE, its most comprehensive and advanced software portfolio for oncology departments and clinics, including radiation therapy planning, comprehensive treatment management, and delivery. It brings all Elekta software products, solutions and services under one umbrella providing all users with one unified software experience. Previously, many cancer clinics have wrestled with stand-alone, closed systems, each with a different purpose. The result has been an unfavorable user experience and steep learning curve, adding pressure to an already strained resource: the clinical team. Elekta ONE aims to improve efficiency in the clinic by as much as 50%, eventually through smarter workflows, increased automation, and by learning from every patient treated. Its workflow-driven approach and deep integration between applications allows information to flow freely, giving clinicians a seamless user experience.
Buying Opportunity • May 09Now 21% undervaluedOver the last 90 days, the stock is up 13%. The fair value is estimated to be €9.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 9.7%. For the next 3 years, revenue is forecast to grow by 7.4% per annum. Earnings is also forecast to grow by 23% per annum over the same time period.
Reported Earnings • Feb 26Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr4.34b (up 20% from 3Q 2022). Net income: kr216.0m (down 5.7% from 3Q 2022). Profit margin: 5.0% (down from 6.4% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 8% per year.
Valuation Update With 7 Day Price Move • Feb 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €7.73, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €12.31 per share.
Upcoming Dividend • Feb 17Upcoming dividend of kr1.20 per share at 3.1% yieldEligible shareholders must have bought the stock before 24 February 2023. Payment date: 02 March 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (4.6%). Higher than average of industry peers (1.7%).
공시 • Feb 14Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter.Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter on February 13, 2023. The first quarter of Elekta’s fiscal year 2023-2024.
공시 • Dec 13First Ever Patient Treated for Pancreatic Cancer with New Advanced Radiotherapy Motion Management Using Elekta Unity MR-LinacElekta AB (publ) announced that UTRECHT - A milestone was reached in radiation therapy last week as the first patients completed their full course of radiation therapy treatment with Elekta (EKTA-B.ST) Unity MR-Linac using Comprehensive Motion Management (CMM) with True Tracking and automatic gating functionalities. A patient with pancreatic cancer was treated at University Medical Center (UMC) Utrecht using Unity's CMM developments, which can continuously calculate the movement of the tumor and correct for it automatically. This first ever treatment delivery using CMM went smoothly and did not increase the total treatment time per fraction. The beam wasautomatically turned on when the patient was in the exhale phase of breathing, so they were not required to hold their breath for extended periods, according to Dr. Martijn Intven, a radiation oncologist at UMC Utrecht. With automatic gating, supported by Elekta's unique True Tracking algorithms, the radiation beam is automatically turned off when the tumor moves outside of the beam, ensuring treatment is always focused on the target. For the first time ever in radiotherapy, Elekta Unity's True Tracking provides continuous tracking of the 3D position of a target anywhere in the body, non-invasively and without surrogates. In addition, CMM offers rapid compensation for sustained intrafraction drift: realigning the beam with the new position of the target without the need to re-acquire a 3D image. UMC Utrecht was Elekta's initial research partner in the development of Elekta Unity, aproject that has extended over two decades. During this time, clinicians at UMC have helped pioneer radiation treatment that responds to movement of tumors during delivery.
Reported Earnings • Nov 25Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr4.08b (up 10% from 2Q 2022). Net income: kr122.0m (down 68% from 2Q 2022). Profit margin: 3.0% (down from 10% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.
공시 • Nov 24Elekta AB (publ), Annual General Meeting, Aug 24, 2023Elekta AB (publ), Annual General Meeting, Aug 24, 2023.
공시 • Nov 18Swedish and Jordanian Royalty Inaugurate Elekta AB (publ) Radiation Therapy Devices for Cancer and Brain DiseaseDignitaries from Sweden and Jordan attended the inauguration of two of Elekta's cancer care technologies, including an advanced linear accelerator used to deliver radiation to treat people with cancer and a Leksell Gamma Knife radiosurgery system, which is used to treat a range of neurosurgical and oncological brain indications. The ceremony was held on November 16 at King Hussein Cancer Center together with King Hussein Cancer Foundation in Amman. Representing Elekta, Caroline Leksell Cooke, Member of Elekta's Board of Directors and granddaughter of Professor Lars Leksell, inventor of the Gamma Knife, spoke of her pride in the company's collaboration with health care facilities in Jordan and support to improve the lives of some of the 11,500 people diagnosed with cancer each year. The first Elekta linac and Gamma Knife were installed in Jordan in 2005, with successive upgrades and new technology since. Today, a wide spectrum of cancer is managed with the country's 15 Elekta linacs, two Gamma Knife systems, and brachytherapy solutions. Their Majesties the King and Queen of Sweden, Her Royal Highness Princess Ghida Talal, who is Chairperson of KHCC, His Royal Highness Prince Talal bin Muhammad, Caroline Leksell Cooke, the Swedish Ambassador to Jordan H.E. Alexandra Rydmark, and Dr. Asem Mansour KHCC General Director, were among those attending the event. The inauguration ceremony was part of a three-day state visit by Sweden's King Carl XVI Gustaf and Queen Silvia, together with Sweden's Minister of Foreign Affairs, H.E.Tobias Billström. During their visit, they will also pay tribute to the 40th anniversary of Sweden's diplomatic presence in Jordan.
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Director Kelly Londy was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Oct 28Elekta AB (publ) Announces Elekta Esprit Receives FDA 510(k) ClearanceElekta AB (publ) announced that Elekta Esprit, a new Leksell Gamma Knife® radiosurgery platform, received FDA 510(k) clearance. This milestone makes the system available to clinicians and people with brain disease in the U.S., as well as opening the door to other countries where FDA approval is recognized. Leksell Gamma Knife has been designed as a gentler alternative to open surgery and conventional radiotherapy. It can target the smallest and most challenging intracranial tumors and lesions with minimal effect on healthy tissue. This vital precision safeguards motor, sensory and neurocognitive function to help protect the mind and the person. With a variety of innovations now available in a single platform, Esprit continues to offer clinicians the option of frameless or frame-based workflows with a frame that provides superior visualization. Remote accessibility and collaboration tools for the treatment team are designed to meet the needs of changing environments. Esprit provides the accuracy to treat even the most challenging targets while delivering a gentler more personalized approach to radiosurgery. Leksell Gamma Knife has over 50 years of clinical evidence and remains the gold standard of intracranial radiosurgery. The U.S. has the largest installed base of Gamma Knife systems, whose users have contributed to driving the standard of care forward. Continuous advances in its design have resulted in extremely fast automated treatment planning for clinicians, and Esprit is ideal for safely treating a broad range of indications, including multiple metastases, arteriovenous malformations, trigeminal neuralgia and vestibular schwannoma.
공시 • Oct 26Elekta Unity Demonstrates Promising Quality of Life Outcomes for Pancreas and Prostate Cancers At Astro Annual MeetingElekta announced two new reports from the MOMENTUM Study highlighting the clinical impact of Elekta Unity MR-Linac in treating pancreas and prostate cancers. The abstracts were presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting, in San Antonio, Texas. These reports add to a growing body of evidence showing that enhanced precision radiotherapy using MR-guided on-line adaptation may improve outcomes in both pancreas and prostate cancers, two common treatment indications for radiotherapy. Elekta Unity is the world’s first and only MR-Linac to unite diagnostic quality high field (1.5T) MRI with a linear accelerator to deliver unprecedented visibility and precision, thus enabling personalized radiotherapy. The MOMENTUM Study is the largest prospective international registry of high field MR-guided therapy, currently enrolling patients from 15 major cancer centers in North America, Europe and Australia. In the study of pancreas tumors, which are historically treatment resistant, 80 patients treated with an ablative radiation dose using MR-guided online adaption were enrolled and surveyed using standardized quality-of-life questionnaires. Patients reported limited adverse effects and stable global health status out to three months. Importantly, 67% of patients were alive one year after the end of treatment. In the study of prostate cancers, 218 patients were enrolled and followed with standardized quality-of-life questionnaires. Approximately half of the patients were treated using both MR-guidance and on-line adaptation functionality on Elekta Unity while the remaining half were treated using only MR-guidance without on-line adaptation. As expected, investigators observed a decline in quality-of-life scores three months after the end of treatment in the cohort treated with MR-guidance alone. However, no significant decline in quality of life was observed in the cohort of prostate cancers treated using both MR-guidance and on-line adaptation.
공시 • Sep 19Elekta AB (publ)(OM:EKTA B) dropped from FTSE All-World Index (USD)Elekta AB (publ)(OM:EKTA B) dropped from FTSE All-World Index (USD)
공시 • Aug 26+ 1 more updateElekta AB (publ) Elects Kelly Londy as a DirectorElekta AB (publ) announced that Kelly Londy was elected as a new Director at its Annual General Meeting held on 25 August 2022.
Reported Earnings • Aug 26First quarter 2023 earnings released: EPS: kr0.16 (vs kr0.33 in 1Q 2022)First quarter 2023 results: EPS: kr0.16 (down from kr0.33 in 1Q 2022). Revenue: kr3.33b (up 11% from 1Q 2022). Net income: kr60.0m (down 53% from 1Q 2022). Profit margin: 1.8% (down from 4.2% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 8.5%, compared to a 7.8% growth forecast for the Medical Equipment industry in Germany.
Upcoming Dividend • Aug 19Upcoming dividend of kr1.20 per shareEligible shareholders must have bought the stock before 26 August 2022. Payment date: 01 September 2022. Payout ratio is on the higher end at 79%, and the cash payout ratio is above 100%. Trailing yield: 3.3%. Lower than top quartile of German dividend payers (4.5%). Higher than average of industry peers (1.2%).
Reported Earnings • Jul 13Full year 2022 earnings released: EPS: kr3.02 (vs kr3.28 in FY 2021)Full year 2022 results: EPS: kr3.02 (down from kr3.28 in FY 2021). Revenue: kr14.5b (up 5.7% from FY 2021). Net income: kr1.15b (down 8.0% from FY 2021). Profit margin: 7.9% (down from 9.1% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 9.4%, compared to a 8.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
공시 • Jul 09+ 1 more updateElekta AB (publ) to Report Fiscal Year 2023 Results on May 25, 2023Elekta AB (publ) announced that they will report fiscal year 2023 results on May 25, 2023
Reported Earnings • May 26Full year 2022 earnings released: EPS: kr3.02 (vs kr3.28 in FY 2021)Full year 2022 results: EPS: kr3.02 (down from kr3.28 in FY 2021). Revenue: kr14.5b (up 5.7% from FY 2021). Net income: kr1.15b (down 8.0% from FY 2021). Profit margin: 7.9% (down from 9.1% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 8.4%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
공시 • May 26Elekta AB (Publ) Proposes Dividend for the Fiscal Year 2021/22The Board of Directors of Elekta AB (publ) proposed a dividend of SEK 2.40 (SEK 2.20) per share (paid in two installments) for the fiscal year 2021/22.
공시 • May 08Elekta Launches New Radiosurgery System: Elekta EspritElekta AB (publ) has evolved radiosurgery to an unprecedented level with the launch of Elekta Esprit. This latest and most advanced system will offer significantly faster automated treatment planning for clinicians, more personalized and patient-friendly treatments, and a degree of precision able to protect the mind and the person. With a variety of innovations now available in a single platform, Esprit offers clinicians superior visualization, as well as remote accessibility and collaboration tools for the treatment team. And it provides the accuracy to treat even the most challenging targets while delivering a gentler more personalized approach to radiosurgery.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Director Cecilia Wikström was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Apr 26+ 2 more updatesElekta AB (publ) to Report Fiscal Year 2022 Final Results on Jul 08, 2022Elekta AB (publ) announced that they will report fiscal year 2022 final results on Jul 08, 2022
Recent Insider Transactions • Mar 10President of Brachy Solutions recently bought €30k worth of stockOn the 2nd of March, John Lapré bought around 4k shares on-market at roughly €7.41 per share. In the last 3 months, there was an even bigger purchase from another insider worth €145k. Insiders have collectively bought €2.1m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Mar 04Insider recently bought €49k worth of stockOn the 24th of February, Verena Schiller bought around 6k shares on-market at roughly €7.58 per share. In the last 3 months, there was an even bigger purchase from another insider worth €145k. Insiders have collectively bought €2.1m more in shares than they have sold in the last 12 months.
Reported Earnings • Feb 25Third quarter 2022 earnings: Revenues in line with analyst expectationsThird quarter 2022 results: Revenue: kr3.60b (flat on 3Q 2021). Net income: kr229.0m (down 29% from 3Q 2021). Profit margin: 6.4% (down from 9.0% in 3Q 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 11%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
공시 • Feb 24Elekta AB (publ), Annual General Meeting, Aug 25, 2022Elekta AB (publ), Annual General Meeting, Aug 25, 2022.
Valuation Update With 7 Day Price Move • Feb 19Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €7.79, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 29x in the Medical Equipment industry in Germany. Total loss to shareholders of 32% over the past three years.
Upcoming Dividend • Feb 18Upcoming dividend of kr1.10 per shareEligible shareholders must have bought the stock before 25 February 2022. Payment date: 03 March 2022. Payout ratio is a comfortable 72% and the cash payout ratio is 80%. Trailing yield: 2.6%. Lower than top quartile of German dividend payers (3.3%). Higher than average of industry peers (1.1%).
Recent Insider Transactions • Dec 18President & CEO recently bought €145k worth of stockOn the 16th of December, Gustaf Salford bought around 14k shares on-market at roughly €10.38 per share. In the last 3 months, there was an even bigger purchase from another insider worth €4.8m. Gustaf has been a buyer over the last 12 months, purchasing a net total of €301k worth in shares.